Melanoma / William H. Sharfman, guest editor.

Includes bibliographical references and index.

Preventing melanoma / Barbara Summerer, Sewon Kang, and Timothy Wang -- Evolution of the melanoma staging system / Rohit R. Sharma, Glen C. Balch, and Charles M. Balch -- Less common variants of cutaneous melanoma / Raymond L. Barnhill, G. Peter Sarantopoulos, and Kapil Gupta -- Controversies in the management of the regional node basin in cutaneous melanoma / Ioannis Hatzaras and Julie R. Lange -- Adjuvant therapy for melanoma / Tara C. Gangadhar and Lynn M. Schuchter -- RAF kinase inhibitor therapy in melanoma / James J. Harding and Paul B. Chapman -- Emerging targets for melanoma therapy besides BRAF / Young Kwang Chae, Sapna P. Patel, and Kevin B. Kim -- Ipilimumab : the new frontier of T-cell antibodies : a paradigm shift in immuno-oncology / Steven J. O'Day -- Adoptive cell transfer immunotherapy for patients with metastatic melanoma / Crystal J. Hessman [and others] -- Immunotherapies for metastatic melanoma / Kevin Conlon -- Updated approach to the patient with metastatic melanoma / Rodabe N. Amaria and Rene Gonzalez.

This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of melanoma treatment. Due to recent drug approvals and increasing ability to offer combined agents, there are many more treatment options available to melanoma patients than even a few years ago. Especially significant are the recent FDA approval of the immunotherapeutic agent ipilimumab for metastatic melanoma, and new agents targeting the BRAF gene in malignant melanoma. There is also coverage of the most recent data pertaining to surgical management, staging and prevention, an.

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide